FGFR2- Related Bent Bone Dysplasia

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 23 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Article Summary

FGFR2-related bent bone dysplasia is a very rare genetic bone disorder. It starts before birth. A single gene called FGFR2 has a harmful change (a mutation). This change upsets normal bone growth. As a result, many bones form in an unusual way. Long bones in the arms and legs look bent. The skull bones can fuse too early (craniosynostosis) and may be poorly mineralized (soft)....

Key Takeaways

  • This article explains Other names in simple medical language.
  • This article explains Types in simple medical language.
  • This article explains Causes in simple medical language.
  • This article explains Common signs and symptoms in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

FGFR2-related bent bone dysplasia is a very rare genetic bone disorder. It starts before birth. A single gene called FGFR2 has a harmful change (a mutation). This change upsets normal bone growth. As a result, many bones form in an unusual way. Long bones in the arms and legs look bent. The skull bones can fuse too early (craniosynostosis) and may be poorly mineralized (soft). The collarbones and the pubic bones can be small (hypoplastic). Bones can look thin and weak (osteopenia). Babies often have special facial features such as a flat midface, small chin, and eyes that look far apart. Teeth may appear very early before birth. Many affected pregnancies sadly end in stillbirth or the baby dies soon after birth, although a few children have survived with serious medical needs. The condition usually happens as a new (de novo) mutation and follows autosomal dominant inheritance. Most known disease-causing changes sit in the transmembrane part of the FGFR2 protein. NCBI+4Orpha.net+4Cell+4

FGFR2-related bent bone dysplasia is a very rare genetic disorder caused by harmful changes (pathogenic variants) in the FGFR2 gene. Babies usually show poor skull mineralization, early fusion of skull bones (craniosynostosis), under-developed collarbones and pubic bones, low bone density, and bent long bones, especially the thigh bones. Facial features can include low-set ears, wide-spaced eyes, midface under-development, tiny jaw, and sometimes early “fetal teeth.” Many pregnancies end before or shortly after birth, but a few long-term survivors are reported. The condition is autosomal dominant, typically from a new (de novo) mutation, and in BBDS1 the FGFR2 variants cluster in the transmembrane domain. Wiley Online Library+3Orpha.net+3Genetic Rare Diseases Center+3

Scientists first defined this syndrome in 2012 and later showed that the mutant FGFR2 has unusual nucleolar activity that boosts ribosomal RNA production and disrupts normal bone development. These mutations act differently from classic craniosynostosis FGFR2 variants by retargeting the receptor to the nucleolus, changing cell behavior in cartilage and bone. Animal and cell studies are helping explain why bones bend and mineralize poorly in this disease. PMC+2OUP Academic+2

Other names

This condition appears in the literature with several names that mean the same thing:

  • Bent Bone Dysplasia—FGFR2 type

  • FGFR2-related bent bone dysplasia

  • Bent Bone Dysplasia Syndrome 1 (BBDS1)

  • Perinatal-lethal bent bone dysplasia (FGFR2) (describes the severe end of the spectrum)

  • ORPHA:313855; OMIM:614592 (database identifiers)

These labels are used across Orphanet, OMIM/Malacards, and clinical genetics resources. Orpha.net+2MalaCards+2

Types

There is no official set of clinical subtypes within FGFR2-related bent bone dysplasia. Doctors usually describe a spectrum:

  1. Classic/perinatal-lethal presentation – severe before birth, bent femurs and other long bones, very soft skull bones, under-mineralized skeleton, small collarbones and pubic bones, and high risk of stillbirth or death soon after delivery. Cell+1

  2. Attenuated/postnatal survivors (rare) – a few children survive infancy but need major care. They often develop multisutural craniosynostosis, raised intracranial pressure, and require neurosurgical procedures (e.g., cranial vault remodeling, shunting). Skeletal problems and feeding/airway issues are common. Wiley Online Library

Note: A different condition called Bent Bone Dysplasia Syndrome 2 (BBDS2) looks similar on X-rays but is caused by a different gene (LAMA5). It is not FGFR2-related; it is listed here only to avoid confusion. National Organization for Rare Disorders

  • Single-gene cause: Harmful variants in FGFR2 change how this receptor works during early bone formation. Most known BBDS1 variants cluster in the transmembrane domain. NCBI+1

  • Signaling problem: Unlike other FGFR2 disorders that increase “canonical” FGF signaling, BBDS1 shows deficient canonical signaling and abnormal nuclear/nucleolar activity of FGFR2 that disturbs bone-forming cells and ribosome production. PMC+1

  • Developmental result: These molecular problems disrupt both endochondral (long bone) and intramembranous (skull) ossification, leading to bent long bones and craniosynostosis. Studies suggest disrupted musculoskeletal integration also contributes to the bent appearance. PMC

Causes

Because this is a single-gene disorder, “causes” here means the different genetic and biological factors that lead to or shape the disease.

  1. FGFR2 mutation (root cause): A harmful change in the FGFR2 gene triggers the disorder. Cell

  2. De novo origin: The mutation usually happens for the first time in the child (not inherited). Cell

  3. Autosomal dominant effect: One altered copy is enough to cause disease. NCBI

  4. Transmembrane-domain hotspot: Disease variants cluster here and disturb receptor behavior. NCBI

  5. Deficient canonical FGFR signaling: Key growth signals to bone cells are reduced. PMC

  6. Abnormal nuclear/nucleolar signaling: Mislocalized FGFR2 in the nucleus/nucleolus changes cell programs. OUP Academic

  7. Increased ribosomal RNA output: Disturbed ribosome biogenesis stresses developing bone tissue. OUP Academic

  8. Altered osteoblast differentiation: Bone-forming cells cannot mature properly. PMC

  9. Disrupted musculoskeletal integration: Bones, muscles, and tendons fail to coordinate growth, causing bending. PMC

  10. Faulty endochondral ossification: Long bones develop abnormally, leading to bowing. PMC

  11. Impaired intramembranous ossification: Skull plates stay soft or fuse wrongly. PMC

  12. Early skull suture fusion (craniosynostosis): Brain growth pressures bones into abnormal shapes. Orpha.net

  13. Undermodeled clavicles/pubic bones: Poor shaping leaves these bones small. MalaCards

  14. Osteopenia: Thin bone mineral makes fractures and deformity more likely. MalaCards

  15. Airway and chest wall effects: Abnormal ribs and midface can impair breathing. (Inferred from skeletal pattern reported.) Cell

  16. Feeding problems: Jaw and palate differences can hinder feeding and growth. (Clinical series report postnatal challenges.) Wiley Online Library

  17. Polyhydramnios and prematurity: Common in affected pregnancies and linked to poorer outcomes. ResearchGate

  18. Parental mosaicism (rare): A parent may carry the variant in some cells without obvious signs and pass it on. (General genetic principle for de novo AD disorders; clinicians consider this in counseling.) NCBI

  19. Modifier genes/environment (theoretical): May shape severity but are not proven specific causes yet. (Expert inference; core cause remains FGFR2.)

  20. Clinical care delays: Late recognition of craniosynostosis or airway issues can worsen course; timely care matters. (Clinical reports of survivors note neurosurgical needs.) Wiley Online Library

Common signs and symptoms

  1. Bent long bones: Arms and legs show bowing on prenatal ultrasound and X-rays, especially the femurs. Cell

  2. Soft skull bones: The calvarium is poorly mineralized, so the head feels soft and X-rays look thin. MalaCards

  3. Craniosynostosis: Skull sutures fuse too early, raising brain pressure and altering head shape. Orpha.net

  4. Midface hypoplasia: The middle part of the face is flat; this can affect airway and feeding. MalaCards

  5. Micrognathia: A small lower jaw can contribute to breathing and feeding problems. MalaCards

  6. Hypertelorism/proptosis: Eyes may look widely spaced or prominent due to skull shape. MalaCards

  7. Low-set or abnormal ears: Ear shape/position differences are reported. hnl.com

  8. Prenatal/early teeth and gum changes: Teeth can erupt unusually early (prenatal teeth) and gums may be overgrown. hnl.com

  9. Small clavicles and pubic bones: These bones are underdeveloped on imaging. MalaCards

  10. Osteopenia: Bones look thin and fragile on X-ray or DXA scans. MalaCards

  11. Short limbs and growth restriction: Limb length and overall growth can be reduced. Cell

  12. Respiratory distress: Airway shape, chest wall changes, and weak bone structure can cause breathing problems soon after birth. Cell

  13. Feeding difficulties/failure to thrive: Jaw and palate problems often require special feeding plans or procedures. Wiley Online Library

  14. Neurologic pressure effects: Raised intracranial pressure from multisuture craniosynostosis may need shunting or cranial surgery in survivors. Wiley Online Library

  15. Perinatal death (common) with rare survivors: Many babies are stillborn or die soon after delivery; a few survive with complex needs. DoveMed+1

Diagnostic tests

A) Physical examination (bedside assessment)

  1. General newborn exam: Check breathing, feeding, tone, and overall growth; look for bent arms/legs and small collarbones. Guides urgent care and baseline severity. Cell

  2. Head shape and scalp exam: Feel the skull bones and sutures; a soft, thin skull or ridged sutures suggest poor mineralization and craniosynostosis. Orpha.net

  3. Craniofacial inspection: Look for flat midface, small jaw, widely spaced eyes, and ear differences; these features support the diagnosis. MalaCards

  4. Chest and airway exam: Watch for retractions, stridor, or weak cry; airway compromise is common and needs urgent attention. Cell

  5. Musculoskeletal exam of limbs: Document bowing, joint range of motion, limb lengths, and any fractures. Helps track progression and plan imaging. Cell

B) Manual/bedside clinical tests (simple measurements and screens)

  1. Head circumference and growth charts: Monitor head growth versus age; abnormal trends may signal rising intracranial pressure in survivors. Wiley Online Library

  2. Suture palpation & transillumination: Gently feel sutures and use a light to assess thin skull areas; suggests hypomineralization or fused sutures. Orpha.net

  3. Feeding/airway screening (bedside swallow, positioning tests): Identifies aspiration risk and need for specialized feeding. (Common in craniofacial skeletal conditions.) Wiley Online Library

  4. Hearing screen (OAE bedside): Early screen for hearing loss that can accompany craniofacial differences; formal ABR follows if abnormal. Cell

  5. Pain/fracture checks: Gentle palpation for pain when an area is touched or pressed. সহজ বাংলা: চাপ দিলে ব্যথা।" data-rx-term="tenderness" data-rx-definition="Tenderness means pain when an area is touched or pressed. সহজ বাংলা: চাপ দিলে ব্যথা।">tenderness or crepitus due to osteopenia-related fractures; triggers radiographs. MalaCards

C) Laboratory & pathological/genetic tests

  1. Targeted FGFR2 sequencing (postnatal): Confirms the exact disease-causing variant; most are in the transmembrane domain. NCBI+1

  2. Prenatal diagnostic testing (CVS/amniocentesis): If a familial variant is known, test fetal DNA to confirm diagnosis before birth. NCBI

  3. Broad exome/Genome testing: When the diagnosis is unclear, exome/genome helps detect FGFR2 variants among skeletal dysplasias. (Widely used in rare skeletal disorders.) NCBI

  4. Bone health labs (supportive): Calcium, phosphate, alkaline phosphatase, vitamin D—to rule out other metabolic bone causes; BBDS1 itself is genetic, but labs guide supportive care. (Clinical practice rationale.)

  5. Pathology of bone (rarely): If obtained, histology may show undermodeled bone; diagnosis remains genetic-imaging driven. (Context from radiographic/clinical series.) Wiley Online Library

D) Electrodiagnostic/physiologic tests

  1. Auditory Brainstem Response (ABR): Objective test for hearing pathway function, important in craniofacial syndromes and reported series. Cell

  2. Polysomnography (sleep study): Checks for obstructive sleep apnea from midface/jaw problems, guiding airway interventions in survivors. (Craniofacial care standard.) Wiley Online Library

  3. Continuous pulse oximetry/capnography: Monitors oxygen and CO₂ in the neonatal period and peri-operative care for breathing safety. (Supportive standard.)

E) Imaging tests

  1. Prenatal ultrasound (2D/3D) and fetal MRI: Detects bowed long bones, small clavicles/pubic bones, soft skull, polyhydramnios, and other clues before birth. ResearchGate

  2. Postnatal skeletal survey + cranial CT (with 3D when needed): X-rays confirm bent long bones and undermodeled bones; CT defines which sutures are fused and helps plan surgery. DXA can quantify osteopenia. Wiley Online Library+1

Non-pharmacological treatments (therapies & others)

Important: Because BBDS1 is often perinatal-lethal, many of the following apply to pregnancy planning, delivery, or rare longer-term survivors. They are supportive strategies, not cures.

  1. Pre-test genetic counseling (before or early in pregnancy).
    Purpose: Explain inheritance, testing options, and likely outcomes in clear, compassionate terms. Mechanism: Uses family history and risk models to set expectations; if a prior child was affected, discusses recurrence risk and reproductive choices. NCBI

  2. High-resolution fetal ultrasound with serial follow-up.
    Purpose: Watch bone shape, skull mineralization, amniotic fluid, and growth to guide delivery planning. Mechanism: Imaging detects bent femurs, hypomineralized calvarium, and associated complications (e.g., polyhydramnios), helping time interventions and counsel the family. Wiley Online Library

  3. Fetal MRI (selected cases).
    Purpose: Clarify skeletal and craniofacial findings when ultrasound is limited. Mechanism: MRI offers better soft-tissue contrast for craniofacial structures and chest, supporting delivery planning at a tertiary center. Wiley Online Library

  4. Diagnostic molecular testing of FGFR2.
    Purpose: Confirm BBDS1 and distinguish it from BBDS2 and other skeletal dysplasias. Mechanism: Next-generation sequencing or targeted analysis detects pathogenic FGFR2 variants in the transmembrane domain. NCBI+1

  5. Multidisciplinary perinatal care planning.
    Purpose: Align obstetrics, neonatology, anesthesia, genetics, and palliative care on goals of care. Mechanism: Team conferences translate imaging and genetics into a plan for delivery, resuscitation level, and postnatal support. Orpha.net

  6. Neonatal respiratory support (when consistent with family goals).
    Purpose: Stabilize breathing in the immediate newborn period. Mechanism: Standard NICU support (CPAP, ventilator) addresses respiratory compromise that can accompany severe skeletal involvement. Orpha.net

  7. Fragility-aware handling & positioning.
    Purpose: Reduce fracture risk and pain in osteopenic, bent bones. Mechanism: Soft supports, gentle swaddling, avoidance of torsion, and careful transfers following protocols used for severe bone fragility disorders. Genetic Rare Diseases Center

  8. Feeding support & aspiration prevention.
    Purpose: Maintain nutrition while minimizing aspiration risks that can occur with craniofacial anomalies. Mechanism: Lactation support, positional feeding, or temporary tube feeding if required. Genetic Rare Diseases Center

  9. Early craniofacial team assessment (survivors).
    Purpose: Monitor raised intracranial pressure and plan timing of craniosynostosis surgery if feasible. Mechanism: Regular head growth checks and imaging detect pressure signs; the team weighs benefits vs. risks in medically fragile infants. NCBI

  10. Orthopedic care plan.
    Purpose: Manage limb bowing, potential fractures, and function. Mechanism: Custom splints, physical therapy, and—rarely later—guided growth or corrective procedures in survivors. Wiley Online Library

  11. Low-dose, development-appropriate physical therapy (survivors).
    Purpose: Promote safe movement, comfort, and parent training without stressing fragile bones. Mechanism: Gentle range-of-motion within pain-free limits, positioning education, and milestone-oriented strategies. Genetic Rare Diseases Center

  12. Vision & hearing screening (survivors).
    Purpose: Detect sensory issues that can accompany craniofacial syndromes. Mechanism: Audiology and ophthalmology screening guide early interventions (glasses, hearing aids) if needed. NCBI

  13. Dental monitoring (survivors with prenatal/early teeth).
    Purpose: Prevent feeding injury or aspiration from loose early teeth. Mechanism: Pediatric dental consult plans safe management of natal/neonatal teeth. Genetic Rare Diseases Center

  14. Bone health nutrition (when feeding is established).
    Purpose: Ensure adequate calcium, vitamin D, and overall calories for growth. Mechanism: Dietetic input tailors intake; supplements only if clinically indicated by labs. Genetic Rare Diseases Center

  15. Family-centered palliative care (when appropriate).
    Purpose: Align care with family values; optimize comfort and bonding. Mechanism: Symptom control, psychosocial support, and memory-making in life-limiting presentations. Orpha.net

  16. Psychosocial support & bereavement resources.
    Purpose: Support mental health and coping for parents and siblings. Mechanism: Counseling, peer groups for skeletal dysplasia and craniofacial conditions, and community resources. National Organization for Rare Disorders

  17. Genetic counseling after diagnosis.
    Purpose: Discuss recurrence risk and future reproductive choices. Mechanism: Explains de novo vs. parental mosaicism, and options such as IVF with PGT-M, CVS, or amniocentesis in future pregnancies. NCBI

  18. Caregiver education on safe handling.
    Purpose: Reduce accidental injury at home. Mechanism: Practical training for lifting, diapering, bathing, and car-seat positioning for fragile bones. Genetic Rare Diseases Center

  19. Vaccination per schedule (unless contraindicated).
    Purpose: Prevent common infections that can worsen fragile health. Mechanism: Routine immunization pathway with pediatrician oversight. Genetic Rare Diseases Center

  20. Long-term follow-up clinic (survivors).
    Purpose: Coordinate orthopedics, craniofacial, nutrition, therapy, and genetics under one plan. Mechanism: Periodic multi-specialty reviews adjust goals as the child grows. Wiley Online Library

Drug treatments — what the evidence actually says

Crucial context: There are no FDA-approved drugs for FGFR2-related bent bone dysplasia, and no clinical trials showing a medicine that improves survival or bone bending in BBDS1. Any use of drugs should be within research settings or strictly for symptom support (e.g., analgesia, reflux therapy) as directed by a neonatologist. The medicines below are FGFR pathway inhibitors approved for adult cancers with FGFR alterations; they are not indicated for BBDS1. I list them to explain the pathway biology and to avoid misinformation online. Do not apply adult cancer dosing to infants. Orpha.net+1

FGFR-pathway oncology examples (pathway context only; not for BBDS1):

  1. Pemigatinib (PEMAZYRE®).
    Class: FGFR1/2/3 inhibitor (oral). Label indication: adults with cholangiocarcinoma harboring FGFR2 fusions/rearrangements (and certain MLN with FGFR1 rearrangements). Purpose/Mechanism: Blocks aberrant FGFR signaling in tumors; increases serum phosphate as an on-target effect. Adult dosing/time (label): 13.5 mg once daily (intermittent regimen varies by indication/label updates). Side effects: hyperphosphatemia, stomatitis, nail changes, ocular toxicity (central serous retinopathy/RPED), diarrhea, fatigue. Note: Not studied in pediatrics for skeletal dysplasia; not appropriate for neonates. FDA Access Data+1

  2. Futibatinib (LYTGOBI®).
    Class: Irreversible FGFR1-4 inhibitor. Label indication: adults with previously treated intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements. Mechanism: Covalently binds FGFR kinase domain. Adult dosing/time (label): 20 mg once daily. Side effects: nail disorders, hyperphosphatemia, diarrhea, palmar-plantar erythrodysesthesia, ocular issues. Pediatric use: not established; not for BBDS1. FDA Access Data+1

  3. Erdafitinib (BALVERSA®).
    Class: FGFR1-4 inhibitor. Label indication: adults with FGFR-altered urothelial carcinoma. Mechanism: Inhibits FGFR signaling; phosphate rises reflect on-target effect. Adult dosing/time (label): 8 mg daily with uptitration by phosphate monitoring. Side effects: hyperphosphatemia, stomatitis, diarrhea, nail/skin changes, ocular toxicity. Not indicated in pediatric BBDS1. FDA Access Data+2FDA Access Data+2

  4. Infigratinib (TRUSELTIQ™).
    Class: FGFR1-3 inhibitor. Label indication: adults with cholangiocarcinoma with FGFR2 fusions or rearrangements. Adult dosing/time (label review): 125 mg daily, 3-weeks-on/1-week-off. Side effects: hyperphosphatemia, ocular events, nail disorders, GI effects. Not a BBDS1 therapy. FDA Access Data+2FDA Access Data+2

  5. Ponatinib (ICLUSIG®).
    Class: Multikinase TKI (BCR-ABL; off-target FGFR). Label indication: adults with certain refractory Ph+ leukemias. Mechanism: Broad kinase inhibition including FGFR in vitro. Adult dosing/time (label): e.g., 45 mg once daily (with dose-modification guidance). Side effects: arterial occlusive events, hypertension, pancreatitis, cytopenias. Not for BBDS1. FDA Access Data+2FDA Access Data+2

Why this matters: These FGFR inhibitors target oncogenic FGFR signaling in adults, not the developmental nucleolar FGFR2 mis-localization that drives BBDS1. Using them in neonates would be unsafe and scientifically unsupported. Families should not expect benefit from cancer drugs in this genetic skeletal dysplasia. OUP Academic+1

Bottom line: Beyond standard symptom medicines (analgesics, reflux meds, vitamins only if deficient), there is no evidence-based drug list for BBDS1. Treatment plans must be made by a neonatology/genetics/orthopedics team case-by-case. Orpha.net+1

Dietary “molecular supplement

Important: Supplements do not correct a pathogenic FGFR2 mutation. In fragile infants, any supplement should be clinically indicated by labs and guided by a pediatric specialist.

  1. Vitamin D (only if deficient).
    Description & mechanism: Supports calcium absorption and bone mineralization via VDR signaling; deficiency worsens osteopenia but does not cause BBDS1. Dose: Pediatric dosing must be individualized by the clinician. Function: Correct deficiency to support general bone health. Genetic Rare Diseases Center

  2. Calcium (if dietary intake is low).
    Description & mechanism: Provides substrate for bone mineralization; works with vitamin D and PTH signaling; does not straighten bent bones from genetic causes. Dose: Clinician-set based on age and intake. Function: Maintain normal calcium balance. Genetic Rare Diseases Center

  3. Phosphate (only if low).
    Description & mechanism: Mineral partner for hydroxyapatite; balance with calcium is crucial; abnormal phosphate can also emerge with FGFR inhibitors (oncology), illustrating pathway effects. Function: Normalize lab-proven deficiencies. FDA Access Data

  4. Iron (if iron-deficiency anemia).
    Description & mechanism: Supports hemoglobin and growth; deficiency management improves overall resilience; has no disease-specific effect on FGFR2 mutation. Function: Correct deficiency only. Genetic Rare Diseases Center

  5. Folate & B12 (if deficient).
    Description & mechanism: DNA synthesis and cell division cofactors; correcting deficiency supports growth but doesn’t modify BBDS1 genetics. Function: Address documented deficiencies. Genetic Rare Diseases Center

  6. Protein-adequate nutrition.
    Description & mechanism: Sufficient protein provides amino acids for growth; dietitians tailor feeds to avoid aspiration and to match energy needs. Function: Support general growth safely. Genetic Rare Diseases Center

  7. Omega-3 fatty acids (dietary, if feeding established).
    Description & mechanism: General infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।" data-rx-term="inflammation" data-rx-definition="Inflammation is the body’s response to injury, infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।">inflammation, pain, or swelling. সহজ বাংলা: প্রদাহ/ফোলা/ব্যথা কমায়।" data-rx-term="anti-inflammatory" data-rx-definition="Anti-inflammatory means reducing inflammation, pain, or swelling. সহজ বাংলা: প্রদাহ/ফোলা/ব্যথা কমায়।">anti-inflammatory and membrane benefits in pediatric nutrition; no BBDS1-specific effect. Function: Balanced diet component when safe. Genetic Rare Diseases Center

  8. Multivitamin (only if intake is inadequate).
    Description & mechanism: Fills minor gaps; should not replace targeted correction of documented deficiencies. Function: General nutritional adequacy. Genetic Rare Diseases Center

  9. Electrolyte monitoring & repletion.
    Description & mechanism: Carefully corrects sodium, potassium, magnesium when needed; maintains overall physiologic stability. Function: Safe homeostasis. Genetic Rare Diseases Center

  10. Vitamin K (per neonatal protocols).
    Description & mechanism: Standard newborn prophylaxis to prevent bleeding; part of routine care, not BBDS1-specific. Function: Hemostasis. Genetic Rare Diseases Center

Drugs immunity booster / regenerative / stem-cell

There are no approved “immune boosters,” regenerative drugs, or stem-cell medicines for BBDS1. Experimental ideas (e.g., mesenchymal stem cells, gene editing) remain theoretical and are not available for this condition. Families should avoid unregulated stem-cell clinics. Orpha.net

  • Supportive vitamins (e.g., D, K) or iron are used only when deficient to meet normal infant standards—not to treat the genetic disease. Any medication plan must be prescribed by the child’s medical team. Genetic Rare Diseases Center

Surgeries

  1. Cranial vault remodeling / endoscopic suture release (craniosynostosis).
    Procedure: Surgically opens fused skull sutures and reshapes the skull. Why: To protect the brain by preventing or relieving raised intracranial pressure and to improve skull shape when the child is medically stable enough. NCBI

  2. Tracheostomy (selected cases).
    Procedure: Surgical airway through the neck. Why: For long-term breathing support if upper-airway obstruction or craniofacial anatomy prevents safe extubation. NCBI

  3. Feeding tube (gastrostomy) in persistent aspiration/failure to thrive.
    Procedure: Tube placed into the stomach for feeding. Why: Ensures safe nutrition when oral feeding is unsafe. Genetic Rare Diseases Center

  4. Orthopedic corrective procedures (later childhood only if feasible).
    Procedure: Guided growth, osteotomy, or fixation. Why: Address severe functional deformity or pain from long-bone bowing in a survivor. Timing and risk-benefit must be conservative. Wiley Online Library

  5. Dental extraction of unstable natal/neonatal teeth.
    Procedure: Removal of loose early teeth. Why: Prevent aspiration or feeding injury. Genetic Rare Diseases Center

Preventions (what we can and cannot prevent)

We cannot “prevent” a de novo FGFR2 mutation in a specific fetus by lifestyle or diet. Prevention discussions focus on future pregnancies and informed choices. NCBI

  1. Pre-conception genetic counseling to understand recurrence risks and options. NCBI

  2. Parental testing for mosaicism when appropriate after an affected pregnancy. NCBI

  3. Preimplantation genetic testing (PGT-M) with IVF for families who wish to avoid recurrence. NCBI

  4. Prenatal diagnostic testing (CVS/amniocentesis) in future pregnancies. NCBI

  5. Early, high-quality fetal imaging to detect skeletal signs and plan care. Wiley Online Library

  6. Deliver in a tertiary center with NICU and craniofacial/orthopedic support. Orpha.net

  7. Infection prevention for survivors (routine vaccines, hand hygiene). Genetic Rare Diseases Center

  8. Safe handling education to minimize fractures in fragile bones. Genetic Rare Diseases Center

  9. Nutrition oversight to avoid deficiencies that could worsen osteopenia. Genetic Rare Diseases Center

  10. Honest goals-of-care planning to prevent unwanted interventions that do not help the child. Orpha.net

When to see a doctor

  • During pregnancy: If an ultrasound shows bowed long bones, a small or poorly mineralized skull, or other skeletal differences, ask for referral to maternal-fetal medicine and genetics for further imaging and testing. Early counseling helps families plan. Wiley Online Library

  • After birth: Seek urgent care if a newborn has breathing difficulty, poor feeding, unusual head shape, or suspected fractures. Ask for a coordinated plan with neonatology, craniofacial surgery, orthopedics, genetics, and palliative care as appropriate. Orpha.net

What to eat and what to avoid

What to eat (with clinician guidance):
Gentle, development-appropriate nutrition that meets calorie, protein, calcium, and vitamin D needs; texture-modified feeds if aspiration risk; and routine pediatric diet as tolerated. A pediatric dietitian should tailor the plan and only add supplements if labs show a deficiency. Genetic Rare Diseases Center

What to avoid:
Hard-to-chew foods if there are jaw/teeth issues; unsafe thick textures in infants with aspiration risk; unsupervised supplements or internet “bone cures”; and unregulated stem-cell clinics. Always clear changes with the child’s medical team. Genetic Rare Diseases Center

Frequently asked questions

  1. Is there a cure?
    No. There is no curative medicine or supplement for BBDS1 at this time. Care is supportive. Orpha.net

  2. Did I cause this by something I did in pregnancy?
    No. BBDS1 usually results from a new gene change unrelated to diet or routine activities. NCBI

  3. How is it confirmed?
    By genetic testing that finds a harmful FGFR2 variant, often in the transmembrane part of the protein. NCBI

  4. Are there long-term survivors?
    Yes, rarely; case series describe a few children living beyond infancy with specialized care. Wiley Online Library

  5. Can FGFR cancer drugs help?
    No evidence supports their use in BBDS1; they are adult cancer drugs with significant risks. FDA Access Data+2FDA Access Data+2

  6. Is surgery always needed?
    No. Surgery is considered only in medically stable survivors and only when benefits outweigh risks. NCBI

  7. What does “autosomal dominant” mean here?
    One altered FGFR2 copy can cause the condition; most cases are new mutations in the child. NCBI

  8. Could this be another condition?
    Yes—BBDS2 (LAMA5) looks similar but is genetically different; testing distinguishes them. National Organization for Rare Disorders

  9. What specialists do we need?
    Maternal-fetal medicine, neonatology, genetics, craniofacial surgery, orthopedics, nutrition, therapy, and palliative care. Orpha.net

  10. What imaging is used before birth?
    Serial ultrasound and sometimes fetal MRI in specialized centers. Wiley Online Library

  11. Can diet fix bent bones?
    No. Diet only supports general health; it cannot correct the gene change or bone shape. Genetic Rare Diseases Center

  12. Should we pursue intensive life support?
    This is a personal decision best made after counseling on the likely course and options. Orpha.net

  13. Could future gene therapy help?
    Research on FGFR2 biology is active, but no clinical gene therapy exists for BBDS1 yet. OUP Academic

  14. Are fractures common?
    Bones are osteopenic and fragile; careful handling and positioning reduce risk. Genetic Rare Diseases Center

  15. Where can I read more?
    Authoritative summaries and reviews are available from Orphanet, NORD, GeneReviews, and peer-reviewed studies. Orpha.net+2National Organization for Rare Disorders+2

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 21, 2025.

PDF Documents For This Disease Condition

  1. Rare Diseases and Medical Genetics.[rxharun.com]
  2. i2023_IFPMA_Rare_Diseases_Brochure_28Feb2017_FINAL.[rxharun.com]
  3. the-UK-rare-diseases-framework.[rxharun.com]
  4. National-Recommendations-for-Rare-Disease-Health-Care-Summary.[rxharun.com]
  5. History of rare diseases and their genetic.[rxharun.com]
  6. health-care-and-rare-disorders.[rxharun.com]
  7. Rare Disease Registries.[rxharun.com]
  8. autoimmune-Rare-Genetic-Diseases.[rxharun.com]
  9. Rare Genetic Diseases.[rxharun.com]
  10. rare-disease-day.[rxharun.com]
  11. Rare_Disease_Drugs_e.[rxharun.com]
  12. fda-CDER-Rare-Diseases-Public-Workshop-Master.[rxharun.com]
  13. rare-and-inherited-disease-eligibility-criteria.[rxharun.com]
  14. FDA-rare-disease-list.pdf-rxharun.com1 Human-Gene-Therapy-for-Rare Diseases_Jan_2020fda.[rxharun.com]
  15. FDA-rare-disease-lists.[rxharun.com]
  16. 30212783fnl_Rare Disease.[rxharun.com]
  17. FDA-rare-disease-list.[rxharun.com]
  18. List of rare disease.[rxharun.com]
  19. Genome Res.-2025-Steyaert-755-68.[rxharun.com]
  20. uk-practice-guidelines-for-variant-classification-v4-01-2020.[rxharun.com]
  21. PIIS2949774424010355.[rxharun.com]
  22. hidden-costs-2016.[rxharun.com]
  23. B156_CONF2-en.[rxharun.com]
  24. IRDiRC_State-of-Play-2018_Final.[rxharun.com]
  25. IRDR_2022Vol11No3_pp96_160.[rxharun.com]
  26. from-orphan-to-opportunity-mastering-rare-disease-launch-excellence.[rxharun.com]
  27. Rare disease fda.[rxharun.com]
  28. England-Rare-Diseases-Action-Plan-2022.[rxharun.com]
  29. SCRDAC 2024 Report.[rxharun.com]
  30. CORD-Rare-Disease-Survey_Full-Report_Feb-2870-2.[rxharun.com]
  31. Stats-behind-the-stories-Genetic-Alliance-UK-2024.[rxharun.com]
  32. rare-and-inherited-disease-eligibility-criteria-v2.[rxharun.com]
  33. ENG_White paper_A4_Digital_FINAL.[rxharun.com]
  34. UK_Strategy_for_Rare_Diseases.[rxharun.com]
  35. MalaysiaRareDiseaseList.[rxharun.com]
  36. EURORDISCARE_FULLBOOKr.[rxharun.com]
  37. EMHJ_1999_5_6_1104_1113.[rxharun.com]
  38. national-genomic-test-directory-rare-and-inherited-disease-eligibilitycriteria-.[rxharun.com]
  39. be-counted-052722-WEB.[rxharun.com]
  40. RDI-Resource-Map-AMR_MARCH-2024.[rxharun.com]
  41. genomic-analysis-of-rare-disease-brochure.[rxharun.com]
  42. List-of-rare-diseases.[rxharun.com]
  43. RDI-Resource-Map-AFROEMRO_APRIL[rxharun.com]
  44. rdnumbers.[rxharun.com] .
  45. Rare disease atoz .[rxharun.com]
  46. EmanPublisher_12_5830biosciences-.[rxharun.com]

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK208609/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC6279436/
  3. https://rarediseases.org/rare-diseases/
  4. https://rarediseases.info.nih.gov/diseases
  5. https://en.wikipedia.org/w/index.php?title=Category:Rare_diseases
  6. https://en.wikipedia.org/wiki/List_of_genetic_disorders
  7. https://en.wikipedia.org/wiki/Category:Genetic_diseases_and_disorders
  8. https://medlineplus.gov/genetics/condition/
  9. https://geneticalliance.org.uk/support-and-information/a-z-of-genetic-and-rare-conditions/
  10. https://www.fda.gov/patients/rare-diseases-fda
  11. https://www.fda.gov/science-research/clinical-trials-and-human-subject-protection/support-clinical-trials-advancing-rare-disease-therapeutics-start-pilot-program
  12. https://accp1.onlinelibrary.wiley.com/doi/full/10.1002/jcph.2134
  13. https://www.mayoclinicproceedings.org/article/S0025-6196%2823%2900116-7/fulltext
  14. https://www.ncbi.nlm.nih.gov/mesh?
  15. https://www.rarediseasesinternational.org/working-with-the-who/
  16. https://ojrd.biomedcentral.com/articles/10.1186/s13023-024-03322-7
  17. https://www.rarediseasesnetwork.org/
  18. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/rare-disease
  19. https://www.raregenomics.org/rare-disease-list
  20. https://www.astrazeneca.com/our-therapy-areas/rare-disease.html
  21. https://bioresource.nihr.ac.uk/rare
  22. https://www.roche.com/solutions/focus-areas/neuroscience/rare-diseases
  23. https://geneticalliance.org.uk/support-and-information/a-z-of-genetic-and-rare-conditions/
  24. https://www.genomicsengland.co.uk/genomic-medicine/understanding-genomics/rare-disease-genomics
  25. https://www.oxfordhealth.nhs.uk/cit/resources/genetic-rare-disorders/
  26. https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-022-01026
  27. https://wikicure.fandom.com/wiki/Rare_Diseases
  28. https://www.wikidoc.org/index.php/List_of_genetic_disorders
  29. https://www.medschool.umaryland.edu/btbank/investigators/list-of-disorders/
  30. https://www.orpha.net/en/disease/list
  31. https://www.genetics.edu.au/SitePages/A-Z-genetic-conditions.aspx
  32. https://ojrd.biomedcentral.com/
  33. https://health.ec.europa.eu/rare-diseases-and-european-reference-networks/rare-diseases_en
  34. https://bioportal.bioontology.org/ontologies/ORDO
  35. https://www.orpha.net/en/disease/list
  36. https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions
  37. https://www.gao.gov/products/gao-25-106774
  38. https://www.gene.com/partners/what-we-are-looking-for/rare-diseases
  39. https://www.genome.gov/For-Patients-and-Families/Genetic-Disorders
  40. https://geneticalliance.org.uk/support-and-information/a-z-of-genetic-and-rare-conditions/
  41. https://my.clevelandclinic.org/health/diseases/21751-genetic-disorders
  42. https://globalgenes.org/rare-disease-facts/
  43. https://www.nidcd.nih.gov/directory/national-organization-rare-disorders-nord
  44. https://byjus.com/biology/genetic-disorders/
  45. https://www.cdc.gov/genomics-and-health/about/genetic-disorders.html
  46. https://www.genomicseducation.hee.nhs.uk/doc-type/genetic-conditions/
  47. https://www.thegenehome.com/basics-of-genetics/disease-examples
  48. https://www.oxfordhealth.nhs.uk/cit/resources/genetic-rare-disorders/
  49. https://www.pfizerclinicaltrials.com/our-research/rare-diseases
  50. https://clinicaltrials.gov/ct2/results?recrs
  51. https://apps.who.int/gb/ebwha/pdf_files/EB116/B116_3-en.pdf
  52. https://stemcellsjournals.onlinelibrary.wiley.com/doi/10.1002/sctm.21-0239
  53. https://www.nibib.nih.gov/
  54. https://www.nei.nih.gov/
  55. https://oxfordtreatment.com/
  56. https://www.nidcd.nih.gov/health/https://consumer.ftc.gov/articles/
  57. https://www.nccih.nih.gov/health
  58. https://catalog.ninds.nih.gov/
  59. https://www.aarda.org/diseaselist/
  60. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets
  61. https://www.nibib.nih.gov/
  62. https://www.nia.nih.gov/health/topics
  63. https://www.nichd.nih.gov/
  64. https://www.nimh.nih.gov/health/topics
  65. https://www.nichd.nih.gov/
  66. https://www.niehs.nih.gov/
  67. https://www.nimhd.nih.gov/
  68. https://www.nhlbi.nih.gov/health-topics
  69. https://obssr.od.nih.gov/.
  70. https://www.nichd.nih.gov/health/topics
  71. https://rarediseases.info.nih.gov/diseases
  72. https://beta.rarediseases.info.nih.gov/diseases
  73. https://orwh.od.nih.gov/

 

Patient safety assistant

Check your symptom safely

Hi, I am RX Symptom Navigator. I can help you understand what to read next and what warning signs need care.
Warning: Do not use this in emergencies, pregnancy, severe illness, or as a substitute for a doctor. For children or teens, use with a parent/guardian and clinician.
A rural-friendly guide: warning signs, when to see a doctor, related articles, tests to discuss, and OTC safety education.
1 Symptom 2 Severity 3 Safe guidance
First safety question

Is there chest pain, breathing trouble, fainting, confusion, severe bleeding, stroke-like weakness, severe injury, or pregnancy danger sign?

Choose quickly

Browse by body area
Start here: Write or select a symptom. The guide will show warning signs, doctor guidance, diagnostic tests to discuss, OTC safety education, and related RX articles.

Important: This tool is educational only. It cannot diagnose, treat, or replace a doctor. OTC information is not a prescription. In an emergency, contact local emergency services or go to the nearest hospital.

Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Doctor / qualified healthcare provider
Tests to discuss with doctor
  • Basic vital signs: temperature, pulse, blood pressure, oxygen level if needed
  • Relevant blood, urine, imaging, or specialist tests only after clinical assessment
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Back pain care roadmap

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • New leg weakness, numbness around private area, or loss of bladder/bowel control
  • Back pain after major injury, fever, unexplained weight loss, cancer history, or severe night pain
Doctor / service to discuss: Orthopedic/spine specialist, physical medicine doctor, physiotherapist under guidance, or qualified clinician.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Discuss neurological examination first. X-ray or MRI may be needed only when red flags, injury, nerve weakness, or persistent severe symptoms are present.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.
  • Avoid forceful massage or bone-setting when there is weakness, injury, fever, or nerve symptoms.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Is this article a replacement for a doctor?

No. It is educational content only. Patients should consult a qualified clinician for diagnosis and treatment.

When should I seek urgent care?

Seek urgent care for severe symptoms, rapidly worsening condition, breathing difficulty, severe pain, neurological changes, or any emergency warning sign.

References

Add references, clinical guidelines, textbooks, journal articles, or trusted medical sources here. You can edit this area from the RX Article Professional Blocks panel.

More from this topic
  1. Congenital Enterocyte Heparan Sulfate Deficiency

    Congenital? enterocyte heparan sulfate deficiency is a very rare, severe, genetic intestinal disease. In this condition, the small bowel lining cells, called enterocytes, do not show...

    April 3, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  2. Congenital ectropion uveae

    Congenital? ectropion uveae, often shortened to CEU, is a very rare eye condition present from birth. In this condition, the dark pigment layer that normally stays...

    April 2, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  3. Congenital Dyserythropoietic Anemia, Type III

    Congenital? dyserythropoietic anemia?, type III, also called CDA type III, is a very rare inherited blood disease. In this disease, the bone marrow tries to make...

    April 2, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  4. Congenital Dyserythropoietic Anemia Type I

    Congenital? dyserythropoietic anemia?, type I, usually called CDA type I, is a rare inherited blood disease. In this disease, the bone marrow tries to make red...

    April 1, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  5. Congenital Dyserythropoietic Anemia Due to KLF1 Mutation

    Congenital? dyserythropoietic anemia? due to KLF1 mutation is a very rare inherited red blood cell disease. In most reported cases, doctors describe it as congenital? dyserythropoietic...

    April 1, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  6. Congenital Dyserythropoietic Anemia Due to KLF1 Mutation

    Congenital? dyserythropoietic anemia? due to KLF1 mutation is a very rare inherited red blood cell disease. In most reported cases, doctors describe it as congenital? dyserythropoietic...

    April 1, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  7. HEMPAS – Hereditary Erythroblast Multinuclearity with Positive Acid Serum Test

    HEMPAS – Hereditary Erythroblast Multinuclearity with Positive Acid Serum Test is a rare inherited blood disease. Its full old name is hereditary erythroblastic multinuclearity with positive...

    April 1, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  8. Congenital Dyserythropoietic Anemia Type 2

    Congenital? dyserythropoietic anemia? type 2, also called CDA type II, is a rare inherited blood disease. In this disease, the body makes red blood cells in...

    April 1, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  9. Component of Oligomeric Golgi Complex 2–Congenital Disorder of Glycosylation

    Component of oligomeric Golgi complex 2–congenital? disorder of glycosylation is usually called COG2-CDG. It is a very rare inherited metabolic disease. In this disease, both copies...

    April 1, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  10. Congenital Disorder of Glycosylation, Type IIq

    Congenital? disorder of glycosylation, type IIq, is a very rare inherited metabolic disease. It is now also commonly called COG2-CDG because it is caused by harmful...

    April 1, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)